Navigation Links
PerOs obtains USDA Establishment and Product Licenses for it's oral vaccine formulations

MONTREAL, April 8 /PRNewswire/ - The PerOs team is proud to announce the USDA/CVB has granted PerOs an Establishment License for the production of bacterins as well as an autogenous bacterin license utilizing its patented oral delivery formulation methods (Oralject(TM)).

"The approval of our manufacturing facility and our oral vaccine formulation platform in the United States marks a significant milestone for our Company, and we look forward offering these capabilities to the livestock producers and opening new possibilities to the growing aquaculture market, as well as collaborating with traditional animal health companies to expand the oral enablement of the industry as a whole." said Grant Vandenberg, CSO and inventor of Oralject.

PerOs' oral delivery platform focuses on the use of natural products to provide delivery of safe therapeutic and prophylactic compounds. PerOs' formulations are designed to enable the delivery of biological compounds such as vaccines, peptides, and probiotics among others while eliminating the stress associated with handling, injection and other current delivery practices.

This new technology platform will enhance the value of vaccines by offering a labor-minimizing, practical oral delivery approach for the livestock industry and open up new possibilities to the rapidly growing aquaculture market. Oral vaccination will provide animal producers with an innovative tool for disease prevention through vaccination rather than relying on disease treatment using antibiotics.

PerOs' is excited to offer this unique tool to an industry focused on producing safe, healthy food for humans. "Oral delivery will improve the adoption of vaccine usage. Vaccination can now occur when appropriate for disease management rather than based on labor management." said Tom Overbay, Vice President Business Development.

PerOs' first-of-its-kind facility was made possible by the contribution of Benchmark Biolabs development team. Benchmark managed the regulatory interface and established the QA and QC standards while also designing, constructing and, today, operating the PerOs manufacturing facility.

"The work of the Benchmark team was perfect, using their BEAM process flow, they led our technology assets in record time toward regulatory approval." said Ian Kott, Chairman of the Board of PerOs.

About PerOs

PerOs is a U.S.-based biotechnology company that has developed unique formulation methods enabling oral delivery of biopharmaceutical compounds by using naturally occurring products to create a technology platform to break the barrier of bioavailability for oral delivery of complex bioactive compounds.

PerOs, Breaking the barriers of bioavailability

SOURCE Peros Systems Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
2. Botaneco obtains $2.4 million in funding from AVAC
3. Ganeden Biotech Obtains Self-Affirmed GRAS Status for Probiotic Ingredient, GanedenBC30 (Bacillus coagulans GBI-30, 6086)
4. Neptune Technologies & Bioressources Inc. obtains Complementary Medicine approval in Australia for NKO(R)
5. NEXCORE Technology Obtains Licenses for Revolutionary Fluid Management System
6. China Kangtai Cactus Biotech, Inc. Obtains $500,000 Equity Financing
7. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
8. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
9. Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product
10. IsoTis Receives FDA Clearance for Accell Family of Products
11. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
Post Your Comments:
(Date:11/24/2015)... 2015 --> ... "Oligonucleotide Synthesis Market by Product & Services (Primer, Probe, ... DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) ... market is expected to reach USD 1,918.6 Million by ... CAGR of 10.1% during the forecast period. ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... The Academy ... Special Interest Group (SIG), MultiGP, also known as Multirotor Grand Prix, to represent the ... last few years. Many AMA members have embraced this type of racing and several ...
(Date:11/24/2015)... New York , November 24, 2015 ... to a recent market research report released by Transparency ... projected to expand at a CAGR of 17.5% during ... "Non-invasive Prenatal Testing Market - Global Industry Analysis, Size, ... estimates the global non-invasive prenatal testing market to reach ...
(Date:11/24/2015)... CITY , Nov. 24, 2015 /PRNewswire/ - ... "Company") announced today that the remaining 11,000 post-share ... Share Purchase Warrants (the "Series B Warrants") subject ... were exercised on November 23, 2015, which will ... Shares.  After giving effect to the issuance of ...
Breaking Biology Technology:
(Date:11/19/2015)... Nov. 19, 2015  Based on its in-depth analysis ... recognizes BIO-key with the 2015 Global Frost & Sullivan ... & Sullivan presents this award to the company that ... the needs of the market it serves. The award ... and expands on customer base demands, the overall impact ...
(Date:11/18/2015)... PHILADELPHIA , Nov. 18, 2015  As new ... in children, doctors and other healthcare providers face challenges ... counsel families and patients. In addition, as more children ... into a patient,s adulthood and old age. ... The Children,s Hospital of Philadelphia (CHOP) . ...
(Date:11/17/2015)... -- Paris from 17 th ... Paris from 17 th until 19 th ... has invented the first combined scanner in the world which ... surface. Until now two different scanners were required: one for ... on the same surface. This innovation is an ideal ...
Breaking Biology News(10 mins):